Shae Lowry
Physician Assistant · Indiana, PANPI 1740619311
Payments from drug & device makers
Across 138 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$884
- Sumitomo Pharma America, Inc.$768
- Ferring Pharmaceuticals Inc.$183
- Urovant Sciences Inc$167
- Cumberland Pharmaceuticals, Inc.$101
- Tactile Systems Technology Inc$39
- plus $272 from 12 others
What the payments were for
- Food & beverage$2,24993%
- Education$1647%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 43 | $884 |
| Sumitomo Pharma America, Inc. | 51 | $768 |
| Ferring Pharmaceuticals Inc. | 11 | $183 |
| Urovant Sciences Inc | 11 | $167 |
| Cumberland Pharmaceuticals, Inc. | 6 | $101 |
| Tactile Systems Technology Inc | 2 | $39 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $36 |
| Convatec Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $34 |
| Procept Biorobotics Corporation | 1 | $25 |
| Blue Earth Diagnostics | 1 | $21 |
| Pfizer | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| KARL Storz Endoscopy-america | 1 | $18 |
| 180 Medical, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
How this compares
$2,414 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 354 | $216,157 |
| GemtesaVibegron | 78 | $47,892 |
| Mirabegron ErMirabegron | 95 | $42,466 |
| Tamsulosin Hcl | 934 | $19,236 |
| Solifenacin Succinate | 236 | $10,968 |
| Bethanechol Chloride | 93 | $5,102 |
| Methenamine Hippurate | 60 | $4,548 |
| Potassium Citrate ErPotassium Citrate | 40 | $3,502 |
| Finasteride | 187 | $2,951 |
| Silodosin | 15 | $2,828 |
| NitrofurantoinNitrofurantoin Macrocrystal | 119 | $2,728 |
| Testosterone | 14 | $2,341 |
| Oxybutynin Chloride ErOxybutynin Chloride | 107 | $2,054 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 77 | $1,447 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $884 | $216,157354 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $768 | $47,89278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Indiana
- Stacy MoranIndiana$28K
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.